When lower price cards may help ease the stress of large drug fees while in the temporary, they do not address the systemic issues driving up prescription rates within the U.S. Broader plan alterations could deal with the basis causes of soaring drug rates, including not enough transparency in pricing along with the role of intermediaries like PBMs